InterventionsHuman trial

Utreglutide (GL0034) Shows Comparable Tolerability and Efficacy with Different Dose Escalation Regimens in Overweight and Obese Adults with Type 2 Diabetes (T2DM)

ADA Scientific Sessions 2026 Abstract

The paper

THENNATI R, ANDERSEN G, BURADE V et al.

ADA Scientific Sessions 2026 Abstract · 5 Jun 2026

Presented at ADA Scientific Sessions 2026 · Late-breaking 2833-LB

doi.org/10.2337/db26-2833-lb

Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
The New England Journal of Medicine · 4 Oct 2026